血清研究所推出廉价的HPV疫苗Cervavavac,以提高印度的疫苗接种率。 Serum Institute launches affordable HPV vaccine, Cervavac, to boost vaccination rates in India.

印度血清研究所(SII)在Visakapatnam主办了一场“消灭HPV和癌症控制”活动,以提高对人体帕皮洛马病毒(HPV)的认识,这是印度妇女中第二大常见癌症。 The Serum Institute of India (SII) hosted a 'Conquer HPV and Cancer Conclave' in Visakhapatnam to raise awareness about the Human Papillomavirus (HPV), which is the second most common cancer among Indian women. 尽管HPV疫苗已经供应了十多年,但认识低和费用高导致疫苗接种率有限。 Despite the HPV vaccine being available for over a decade, low awareness and high costs have limited vaccination rates. 性免疫倡议开发了一种负担得起的、不分性别的HPV疫苗,名为Cervavavac,旨在提高疫苗接种率,并强调男女接种疫苗对预防各种癌症的重要性。 The SII has developed an affordable, gender-neutral HPV vaccine called Cervavac, aiming to boost vaccination rates and highlight the importance of vaccination for both men and women to prevent various cancers.